Header Logo

Connection

SALIM VIRANI to Atherosclerosis

Back to Details
This is a "connection" page, showing publications SALIM VIRANI has written about Atherosclerosis.
SALIM VIRANI
Connection Strength
30.010
Atherosclerosis
  1. Lipoprotein(a) in clinical practice: A guide for the clinician. Prog Cardiovasc Dis. 2023 Jul-Aug; 79:28-36.
    View in: PubMed
    Score: 0.513
  2. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs. JACC Heart Fail. 2023 08; 11(8 Pt 1):933-942.
    View in: PubMed
    Score: 0.506
  3. With Current Safety and Efficacy Data, Should Statins Be Made Available as Nonprescription Over-the-Counter Drugs? Curr Cardiol Rep. 2023 05; 25(5):423-430.
    View in: PubMed
    Score: 0.501
  4. Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease. Circulation. 2023 05 02; 147(18):1411-1413.
    View in: PubMed
    Score: 0.499
  5. 2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 01 24; 81(3):292-317.
    View in: PubMed
    Score: 0.487
  6. South Asian ethnicity: What can we do to make this risk enhancer a risk equivalent? Prog Cardiovasc Dis. 2022 Nov-Dec; 75:21-32.
    View in: PubMed
    Score: 0.486
  7. Statin Use and Risk of Diabetes by Subclinical Atherosclerosis Burden (from a Multi-Ethnic Study of Atherosclerosis Report). Am J Cardiol. 2022 12 01; 184:7-13.
    View in: PubMed
    Score: 0.485
  8. Association of polygenic risk scores with incident atherosclerotic cardiovascular disease events among individuals with coronary artery calcium score of zero: The multi-ethnic study of atherosclerosis. Prog Cardiovasc Dis. 2022 Sep-Oct; 74:19-27.
    View in: PubMed
    Score: 0.480
  9. Statins and Primary Atherosclerotic Cardiovascular Disease Prevention-What We Know, Where We Need to Go, and Why Are We Not There Already? JAMA Netw Open. 2022 08 01; 5(8):e2228538.
    View in: PubMed
    Score: 0.479
  10. Association Between Social Vulnerability Index and Cardiovascular Disease: A?Behavioral Risk Factor Surveillance System Study. J Am Heart Assoc. 2022 08 02; 11(15):e024414.
    View in: PubMed
    Score: 0.479
  11. Use of Preventive Cardiovascular Health Care Among Asian American Individuals: A National Health Interview Survey Study. Curr Probl Cardiol. 2023 Aug; 48(8):101241.
    View in: PubMed
    Score: 0.471
  12. Association of premature atherosclerotic cardiovascular disease with higher risk of cancer: a behavioral risk factor surveillance system study. Eur J Prev Cardiol. 2022 Mar 25; 29(3):493-501.
    View in: PubMed
    Score: 0.467
  13. Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs). Am J Cardiol. 2022 06 01; 172:7-10.
    View in: PubMed
    Score: 0.467
  14. Evaluation of Factors Underlying Sex-Based Disparities in Cardiovascular Care in Adults With Self-reported Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2022 Mar 01; 7(3):341-345.
    View in: PubMed
    Score: 0.465
  15. Potential Impact of the 2019 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease Recommendations on the Inappropriate Routine Use of Aspirin and Aspirin Use Without a Recommended Indication for Primary Prevention of Cardiovascular Disease in Cardiology Practices: Insights From the NCDR PINNACLE Registry. Circ Cardiovasc Qual Outcomes. 2022 03; 15(3):e007979.
    View in: PubMed
    Score: 0.463
  16. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Prog Cardiovasc Dis. 2022 Jul-Aug; 73:32-40.
    View in: PubMed
    Score: 0.462
  17. Association of Coronary Artery Calcium Density and Volume With Predicted Atherosclerotic Cardiovascular Disease Risk and Cardiometabolic Risk Factors in South Asians: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study. Curr Probl Cardiol. 2023 Apr; 48(4):101105.
    View in: PubMed
    Score: 0.461
  18. Correlates of SGLT-2-inhibitiors use among patients with atherosclerotic cardiovascular disease and type 2 diabetes mellitus: Insights from the department of veterans affairs. Am Heart J. 2022 06; 248:160-162.
    View in: PubMed
    Score: 0.460
  19. Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis. Circulation. 2022 01 25; 145(4):259-267.
    View in: PubMed
    Score: 0.458
  20. Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy. Curr Probl Cardiol. 2022 Jul; 47(7):101043.
    View in: PubMed
    Score: 0.456
  21. Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
    View in: PubMed
    Score: 0.452
  22. Lipoprotein (a): Recent Updates on a Unique Lipoprotein. Curr Atheroscler Rep. 2021 06 19; 23(8):41.
    View in: PubMed
    Score: 0.443
  23. Substance Use and Premature Atherosclerotic Cardiovascular Disease (From the CDC Behavioral Risk Factor Surveillance System [BRFSS] Survey). Am J Cardiol. 2021 08 01; 152:177-178.
    View in: PubMed
    Score: 0.442
  24. Premature Atherosclerotic Cardiovascular Disease Risk Among Patients with Inflammatory Bowel Disease. Am J Med. 2021 08; 134(8):1047-1051.e2.
    View in: PubMed
    Score: 0.437
  25. Contemporary outcomes studies to identify and mitigate the risk in patients with premature cardiovascular disease. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug; 21(4):559-570.
    View in: PubMed
    Score: 0.433
  26. Recreational substance use among patients with premature atherosclerotic cardiovascular disease. Heart. 2021 04; 107(8):650-656.
    View in: PubMed
    Score: 0.433
  27. Facility-Level Variation in Reported Statin-Associated Side Effects Among Patients with Atherosclerotic Cardiovascular Disease-Perspective from the Veterans Affair Healthcare System. Cardiovasc Drugs Ther. 2022 04; 36(2):295-300.
    View in: PubMed
    Score: 0.432
  28. Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther. 2022 02; 36(1):93-102.
    View in: PubMed
    Score: 0.430
  29. Distribution of calcium volume, density, number, and type of coronary vessel with calcified plaque in South Asians in the US and other race/ethnic groups: The MASALA and MESA studies. Atherosclerosis. 2021 01; 317:16-21.
    View in: PubMed
    Score: 0.427
  30. Shared Decisions: A Qualitative Study on Clinician and Patient Perspectives on Statin Therapy and Statin-Associated Side Effects. J Am Heart Assoc. 2020 11 17; 9(22):e017915.
    View in: PubMed
    Score: 0.425
  31. Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System. Cardiovasc Drugs Ther. 2021 06; 35(3):533-538.
    View in: PubMed
    Score: 0.420
  32. Racial and Geographic Disparities in Internet Use in the United States Among Patients with Atherosclerotic Cardiovascular Disease. Am J Cardiol. 2020 11 01; 134:146-147.
    View in: PubMed
    Score: 0.418
  33. Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Netw Open. 2020 08 03; 3(8):e2011051.
    View in: PubMed
    Score: 0.417
  34. Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently? Curr Atheroscler Rep. 2020 07 16; 22(9):44.
    View in: PubMed
    Score: 0.416
  35. Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Curr Atheroscler Rep. 2020 06 03; 22(7):25.
    View in: PubMed
    Score: 0.412
  36. Secondary Prevention for Atherosclerotic Cardiovascular Disease: Comparing Recent US and European Guidelines on Dyslipidemia. Circulation. 2020 04 07; 141(14):1121-1123.
    View in: PubMed
    Score: 0.408
  37. The Way to a Woman's Heart: Assessing, Personalizing, and Reclassifying Atherosclerotic Cardiovascular Disease Risk in Female Patients. Tex Heart Inst J. 2020 04 01; 47(2):125-127.
    View in: PubMed
    Score: 0.407
  38. High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study. J Am Heart Assoc. 2020 02 04; 9(3):e013600.
    View in: PubMed
    Score: 0.403
  39. Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2020 01 11; 22(1):3.
    View in: PubMed
    Score: 0.401
  40. Association between frequency of primary care provider visits and evidence-based statin prescribing and statin adherence: Findings from the Veterans Affairs system. Am Heart J. 2020 03; 221:9-18.
    View in: PubMed
    Score: 0.399
  41. The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. J Clin Lipidol. 2019 Sep - Oct; 13(5):797-803.e1.
    View in: PubMed
    Score: 0.390
  42. Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018?AHA/ACC Cholesterol Guidelines. J Am Coll Cardiol. 2019 08 06; 74(5):712-714.
    View in: PubMed
    Score: 0.389
  43. Relation Between Cardiology Follow-Up Visits, Evidence-Based Statin Prescribing, and Statin Adherence (from the Veterans Affairs Health Care System). Am J Cardiol. 2019 10 15; 124(8):1165-1170.
    View in: PubMed
    Score: 0.389
  44. Childhood Oral Infections and Subclinical Atherosclerosis in Adulthood: Should We Wait for Causality or Just Treat? JAMA Netw Open. 2019 04 05; 2(4):e192489.
    View in: PubMed
    Score: 0.380
  45. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Curr Atheroscler Rep. 2019 04 02; 21(6):20.
    View in: PubMed
    Score: 0.380
  46. 2018 Cholesterol Guidelines: Key Topics in Primary Prevention. Curr Atheroscler Rep. 2019 03 16; 21(5):17.
    View in: PubMed
    Score: 0.379
  47. Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
    View in: PubMed
    Score: 0.378
  48. Low-Density Lipoprotein Cholesterol: Is 160 the New 190? Circulation. 2018 11 20; 138(21):2326-2329.
    View in: PubMed
    Score: 0.371
  49. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. Front Biosci (Landmark Ed). 2018 01 01; 23(6):1099-1112.
    View in: PubMed
    Score: 0.349
  50. Associations of Lipoprotein(a) Levels With Incident Atrial Fibrillation and Ischemic Stroke: The ARIC (Atherosclerosis Risk in Communities) Study. J Am Heart Assoc. 2017 Dec 15; 6(12).
    View in: PubMed
    Score: 0.348
  51. Association Between Modifiable Risk Factors and Pharmaceutical Expenditures Among Adults With Atherosclerotic Cardiovascular Disease in the United States: 2012-2013 Medical Expenditures Panel?Survey. J Am Heart Assoc. 2017 Jun 09; 6(6).
    View in: PubMed
    Score: 0.335
  52. Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the Department of Veterans Affairs. Circulation. 2017 06 20; 135(25):2572-2574.
    View in: PubMed
    Score: 0.333
  53. Mobile Health (mHealth) Technology for the Management of Hypertension and Hyperlipidemia: Slow Start but Loads of Potential. Curr Atheroscler Rep. 2017 Mar; 19(3):12.
    View in: PubMed
    Score: 0.329
  54. Association of body mass index and waist circumference with subclinical atherosclerosis in retired NFL players. South Med J. 2014 Oct; 107(10):633-9.
    View in: PubMed
    Score: 0.278
  55. What is new in the 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic risk in adults? Tex Heart Inst J. 2014 Jun; 41(3):304-5.
    View in: PubMed
    Score: 0.272
  56. How to identify patients with vulnerable plaques. Diabetes Obes Metab. 2008 Sep; 10(10):824-33.
    View in: PubMed
    Score: 0.172
  57. Early-onset atherosclerotic cardiovascular disease. Eur J Prev Cardiol. 2025 Jan 27; 32(2):100-112.
    View in: PubMed
    Score: 0.142
  58. Racial Differences in the Burden of Atherosclerotic Cardiovascular Disease Related to Elevated Lipoprotein(a) Levels: The ARIC Study. Circulation. 2024 Jul 16; 150(3):250-252.
    View in: PubMed
    Score: 0.137
  59. Epidemiology and Prognostic Implications of Coronary Artery Calcium in Asymptomatic Individuals With Prediabetes: A Multicohort Study. Diabetes Care. 2024 Apr 01; 47(4):698-706.
    View in: PubMed
    Score: 0.134
  60. Association of cardiometabolic and vascular atherosclerosis phenotypes on non-contrast chest CT with incident heart failure in patients with severe hypercholesterolemia. J Clin Lipidol. 2024 May-Jun; 18(3):e403-e412.
    View in: PubMed
    Score: 0.133
  61. Development and Validation of the American Heart Association's PREVENT Equations. Circulation. 2024 02 06; 149(6):430-449.
    View in: PubMed
    Score: 0.131
  62. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation. 2023 12 12; 148(24):1982-2004.
    View in: PubMed
    Score: 0.131
  63. Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2023 11 09; 30(16):1731-1740.
    View in: PubMed
    Score: 0.131
  64. Novel Size-Based High-Density Lipoprotein Subspecies and Incident Vascular Events. J Am Heart Assoc. 2023 11 07; 12(21):e031160.
    View in: PubMed
    Score: 0.131
  65. Subclinical atherosclerosis on chest computed tomography and mortality in young patients with severe hypercholesterolemia. Prog Cardiovasc Dis. 2023 Nov-Dec; 81:105-108.
    View in: PubMed
    Score: 0.131
  66. Age-Related Differences in the Contribution of Systolic Blood Pressure and Biomarkers to Cardiovascular Disease Risk Prediction: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Cardiol. 2023 10 01; 204:295-301.
    View in: PubMed
    Score: 0.129
  67. Association Between Historical Neighborhood Redlining and Cardiovascular Outcomes Among US Veterans With Atherosclerotic Cardiovascular Diseases. JAMA Netw Open. 2023 07 03; 6(7):e2322727.
    View in: PubMed
    Score: 0.128
  68. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis. 2023 06; 374:107-120.
    View in: PubMed
    Score: 0.126
  69. Association of Long-term Change in N-Terminal Pro-B-Type Natriuretic Peptide With Incident Heart Failure and Death. JAMA Cardiol. 2023 03 01; 8(3):222-230.
    View in: PubMed
    Score: 0.125
  70. Reclassification of Pre-Heart Failure Stages Using Cardiac Biomarkers: The ARIC Study. JACC Heart Fail. 2023 04; 11(4):440-450.
    View in: PubMed
    Score: 0.124
  71. Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2022 11; 11(21):e026762.
    View in: PubMed
    Score: 0.122
  72. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020. Eur J Prev Cardiol. 2022 10 20; 29(14):1830-1838.
    View in: PubMed
    Score: 0.122
  73. A stepwise approach to prescribing novel lipid-lowering medications. J Clin Lipidol. 2022 Nov-Dec; 16(6):822-832.
    View in: PubMed
    Score: 0.122
  74. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 10 14; 43(39):3925-3946.
    View in: PubMed
    Score: 0.121
  75. Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019. Circ Cardiovasc Qual Outcomes. 2022 12; 15(12):e008861.
    View in: PubMed
    Score: 0.121
  76. World Heart Federation Cholesterol Roadmap 2022. Glob Heart. 2022; 17(1):75.
    View in: PubMed
    Score: 0.121
  77. Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA). J Clin Lipidol. 2022 Nov-Dec; 16(6):870-877.
    View in: PubMed
    Score: 0.121
  78. State-Level Social Vulnerability Index and Healthcare Access in Patients With Atherosclerotic Cardiovascular Disease (from the BRFSS Survey). Am J Cardiol. 2022 09 01; 178:149-153.
    View in: PubMed
    Score: 0.119
  79. Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2022 06; 350:82-89.
    View in: PubMed
    Score: 0.118
  80. Variation in statin prescription among veterans with HIV and known atherosclerotic cardiovascular disease. Am Heart J. 2022 07; 249:12-22.
    View in: PubMed
    Score: 0.117
  81. Reducing Cardiovascular Risk in the Medicare Million Hearts Risk Reduction Model: Insights From the National Cardiovascular Data Registry PINNACLE Registry. Circ Cardiovasc Qual Outcomes. 2022 04; 15(4):e007908.
    View in: PubMed
    Score: 0.117
  82. Discordance Between Standard Equations for Determination of LDL?Cholesterol in Patients With?Atherosclerosis. J Am Coll Cardiol. 2022 02 15; 79(6):530-541.
    View in: PubMed
    Score: 0.116
  83. Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. Am J Med. 2022 05; 135(5):603-606.
    View in: PubMed
    Score: 0.114
  84. Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors: The Multi-Ethnic Study of Atherosclerosis. JAMA Cardiol. 2021 10 01; 6(10):1161-1170.
    View in: PubMed
    Score: 0.113
  85. Scope and Social Determinants of Food Insecurity Among Adults With Atherosclerotic Cardiovascular Disease in the United States. J Am Heart Assoc. 2021 08 17; 10(16):e020028.
    View in: PubMed
    Score: 0.112
  86. Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2021 05 01; 146:15-21.
    View in: PubMed
    Score: 0.108
  87. Novel emerging therapies in atherosclerosis targeting lipid metabolism. Expert Opin Investig Drugs. 2020 Jun; 29(6):611-622.
    View in: PubMed
    Score: 0.103
  88. The relationship between cardiorespiratory fitness, cardiovascular risk factors and atherosclerosis. Atherosclerosis. 2020 07; 304:44-52.
    View in: PubMed
    Score: 0.103
  89. Cumulative Burden of Financial Hardship From Medical Bills Across the Spectrum of Diabetes Mellitus and Atherosclerotic Cardiovascular Disease Among Non-Elderly Adults in the United States. J Am Heart Assoc. 2020 05 18; 9(10):e015523.
    View in: PubMed
    Score: 0.103
  90. Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrol Dial Transplant. 2020 02 01; 35(2):312-319.
    View in: PubMed
    Score: 0.101
  91. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.100
  92. Cost-Related Medication Nonadherence in Adults With Atherosclerotic Cardiovascular Disease in the United States, 2013 to 2017. Circulation. 2019 12 17; 140(25):2067-2075.
    View in: PubMed
    Score: 0.099
  93. High-Sensitive Troponin T, Natriuretic Peptide, and Cognitive Change. J Am Geriatr Soc. 2019 11; 67(11):2353-2361.
    View in: PubMed
    Score: 0.097
  94. The Interplay of the Global Atherosclerotic Cardiovascular Disease Risk Scoring and Cardiorespiratory Fitness for the Prediction of All-Cause Mortality and Myocardial Infarction: The Henry Ford ExercIse Testing Project (The FIT Project). Am J Cardiol. 2019 08 15; 124(4):511-517.
    View in: PubMed
    Score: 0.096
  95. Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J. 2019 08; 214:113-124.
    View in: PubMed
    Score: 0.096
  96. Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiol. 2019 05 01; 4(5):473-477.
    View in: PubMed
    Score: 0.096
  97. Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. J Am Heart Assoc. 2019 04 02; 8(7):e011765.
    View in: PubMed
    Score: 0.095
  98. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocr Rev. 2019 04 01; 40(2):537-557.
    View in: PubMed
    Score: 0.095
  99. Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019 03 01; 4(3):206-213.
    View in: PubMed
    Score: 0.094
  100. Financial Hardship From Medical Bills Among Nonelderly U.S. Adults With Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2019 02 19; 73(6):727-732.
    View in: PubMed
    Score: 0.094
  101. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. Circulation. 2019 06 18; 139(25):e1162-e1177.
    View in: PubMed
    Score: 0.093
  102. Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. JAMA Cardiol. 2018 08 01; 3(8):739-748.
    View in: PubMed
    Score: 0.091
  103. National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel?Survey. J Am Heart Assoc. 2018 01 22; 7(2).
    View in: PubMed
    Score: 0.088
  104. Patient-Provider Communication and Health Outcomes Among Individuals With Atherosclerotic Cardiovascular Disease in the United States: Medical Expenditure Panel Survey 2010 to 2013. Circ Cardiovasc Qual Outcomes. 2017 04; 10(4).
    View in: PubMed
    Score: 0.083
  105. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. Int J Cardiol. 2017 Apr 15; 233:61-66.
    View in: PubMed
    Score: 0.082
  106. Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 01 01; 2(1):47-54.
    View in: PubMed
    Score: 0.081
  107. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey. JAMA Cardiol. 2017 01 01; 2(1):56-65.
    View in: PubMed
    Score: 0.081
  108. Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis. 2016 10; 253:156-163.
    View in: PubMed
    Score: 0.079
  109. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis. 2015 Sep; 242(1):243-50.
    View in: PubMed
    Score: 0.073
  110. Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults: Atherosclerosis Risk in Communities Study. Hypertension. 2015 Sep; 66(3):474-80.
    View in: PubMed
    Score: 0.073
  111. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort. JAMA Intern Med. 2015 Jan; 175(1):138-40.
    View in: PubMed
    Score: 0.071
  112. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):1069-77.
    View in: PubMed
    Score: 0.067
  113. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study. Clin Chem. 2013 Dec; 59(12):1802-10.
    View in: PubMed
    Score: 0.065
  114. Ceruloplasmin and heart failure in the Atherosclerosis Risk in Communities study. Circ Heart Fail. 2013 Sep 01; 6(5):936-43.
    View in: PubMed
    Score: 0.064
  115. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012 Jan 17; 125(2):241-9.
    View in: PubMed
    Score: 0.057
  116. Carotid arterial wall characteristics are associated with incident ischemic stroke but not coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2012 Jan; 43(1):103-8.
    View in: PubMed
    Score: 0.057
  117. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation. 2011 Apr 05; 123(13):1367-76.
    View in: PubMed
    Score: 0.054
  118. Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. Circ Cardiovasc Qual Outcomes. 2021 01; 14(1):e006548.
    View in: PubMed
    Score: 0.027
  119. Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. J Am Coll Cardiol. 2019 10 15; 74(15):1926-1942.
    View in: PubMed
    Score: 0.025
  120. Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. Eur J Prev Cardiol. 2020 10; 27(15):1597-1605.
    View in: PubMed
    Score: 0.024
  121. ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology. 2019 05 28; 92(22):e2580-e2593.
    View in: PubMed
    Score: 0.024
  122. Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. J Clin Lipidol. 2018 Mar - Apr; 12(2):367-374.e3.
    View in: PubMed
    Score: 0.022
  123. A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience. J Clin Lipidol. 2017 May - Jun; 11(3):596-599.
    View in: PubMed
    Score: 0.021
  124. The impact of multiple single day blood pressure readings on cardiovascular risk estimation: The Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2016 09; 23(14):1529-36.
    View in: PubMed
    Score: 0.019
  125. High-sensitivity troponin T and cardiovascular events in systolic blood pressure categories: atherosclerosis risk in communities study. Hypertension. 2015 Jan; 65(1):78-84.
    View in: PubMed
    Score: 0.017
  126. Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke. 2013 Jul; 44(7):1803-8.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.